• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
  • Imfinzi Trial Does Not Meet Primary Endpoint americanpharmaceuticalreview
    February 10, 2021
    The KESTREL Phase III trial for AstraZeneca’s Imfinzi (durvalumab) did not meet the primary endpoint of improving overall survival (OS) versus the EXTREME treatment regimen (chemotherapy plus cetuximab), a standard of care ...
  • Extreme Eating Habits Could Be an Early Clue to Autism drugs
    July 24, 2019
    Lots of kids are picky eaters. But when eating habits in young children are extreme, it could be a sign of autism, researchers say.

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service